75 related articles for article (PubMed ID: 21798783)
1. [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
Romero-Ventosa EY; Mucientes-Molina A; Pedrido-Reino E; Lago-Rivero N; Constenla-Caramés L; Arias-Santos I
Farm Hosp; 2012; 36(2):68-76. PubMed ID: 21798783
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
5. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
8. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
[TBL] [Abstract][Full Text] [Related]
10. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
12. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
13. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Heigener DF; Wu YL; van Zandwijk N; Mali P; Horwood K; Reck M
Lung Cancer; 2011 Nov; 74(2):274-9. PubMed ID: 21439671
[TBL] [Abstract][Full Text] [Related]
14. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Tiseo M; Gridelli C; Cascinu S; Crinò L; Piantedosi FV; Grossi F; Brandes AA; Labianca R; Siena S; Amoroso D; Belvedere O; Valentino B; Bearz A; Venturino P; Ardizzoni A
Lung Cancer; 2009 May; 64(2):199-206. PubMed ID: 18951651
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Merimsky O; Cheng CK; Au JS; von Pawel J; Reck M
Oncol Rep; 2012 Aug; 28(2):721-7. PubMed ID: 22614912
[TBL] [Abstract][Full Text] [Related]
16. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
[TBL] [Abstract][Full Text] [Related]
17. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
20. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Faehling M; Eckert R; Kuom S; Kamp T; Stoiber KM; Schumann C
Oncology; 2010; 78(3-4):249-58. PubMed ID: 20523085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
